EARLY BREAST CANCER

This study compared two radiation methods for people with early-stage breast cancer: a shorter, more focused radiation (accelerated partial breast irradiation) versus standard whole breast radiation. The goal was to see which causes fewer side effects like skin problems, breast s…

This study looked at whether people with early or locally advanced HER2-positive breast cancer prefer receiving their medication (a combination of pertuzumab and trastuzumab) at home versus in the hospital. About 346 participants were randomly assigned to receive the drug at home…

This study looked at 270 women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. Researchers used the OncotypeDX test to see how its recurrence score influenced whether doctors recommended chemotherapy. They also checked if the score was linked to cancer c…

This study examined tumor samples from 3,646 women with early-stage breast cancer who had already received chemotherapy after surgery. Researchers measured specific immune cells (tumor-infiltrating lymphocytes and CD8+ T cells) to see if their presence was linked to how long pati…

This study surveyed 385 women aged 35 or younger with early-stage breast cancer to learn how they feel about the risk of infertility from chemotherapy. The goal was to understand whether they would still choose chemotherapy if it might reduce their chances of having children. The…

This study looked at 171 women with early breast cancer to see if immune cells inside tumors are linked to how well chemotherapy works. Researchers also checked if certain markers in the blood could help predict cancer return. The goal was to better understand which patients migh…

This study involved 155 women with early breast cancer who had been taking hormone therapy for 2-3 years. Researchers wanted to understand how skin-related side effects from the treatment impact their quality of life. Participants filled out questionnaires about their skin sympto…

This study looked at tissue samples from 2751 early breast cancer patients who had already completed chemotherapy. Researchers wanted to see if tumors with low levels of HER2 protein are biologically different from those with no HER2 at all. They used genetic testing and protein …